Table 1. Baseline characteristics of mCRPC patients.
| Variables | Total | Immunohistochemistry | P | |
|---|---|---|---|---|
| ERG(+) | ERG(−) | |||
| No. of patients | 71 (100) | 13 (18.3) | 58 (81.7) | |
| Age at diagnosis, years | 64.9 ± 7.5 [64.0, 49.0-88.0] | 63.5 ± 10.6 [62.0, 49.0-88.0] | 65.2 ± 6.6 [65.5, 52.0-78.0] | 0.450 |
| Gleason score at diagnosis | 0.346 | |||
| 7 | 9 (12.7) | 1 (7.7) | 8 (13.8) | |
| 8 | 19 (26.8) | 3 (23.1) | 16 (27.6) | |
| 9 | 32 (45.1) | 6 (46.1) | 26 (44.8) | |
| 10 | 11 (15.5) | 3 (23.1) | 8 (13.8) | |
| Initial PSA, ng/ml | 775.7 ± 1597.0 [166.6, 4.6-7539.3] | 170.9 ± 174.8 [134.2, 8.7-551.0] | 916.1 ± 1743.6 [225.9, 4.6-7539.3] | 0.003 |
| PSA nadir after ADT | 5.1 ± 11.8 [1.0, 0.01-65.66] | 6.5 ± 8.4 [2.0, 0.07-19.52] | 4.7 ± 12.5 [0.9, 0.01-65.66] | 0.624 |
| Metastatic status before docetaxel treatment | 0.798 | |||
| Low volume | 24 (33.8) | 4 (30.8) | 20 (34.5) | |
| High volume | 47 (66.2) | 9 (69.2) | 38 (65.5) | |
| Type of local treatment | 0.358 | |||
| None | 62 (87.3) | 12 (92.3) | 50 (86.2) | |
| Prostatectomy | 3 (4.2) | 1 (7.7) | 2 (3.5) | |
| HIFU | 6 (8.5) | 0 | 6 (10.3) | |
| ADT duration prior to docetaxel treatment | 28.6 ± 20.6 [22.9, 3.3-94.3] | 22.5 ± 18.3 [17.2, 3.3-66.7] | 30.0 ± 20.9 [23.7, 6.3-94.3] | 0.240 |
| No. of docetaxel regimens | 6.9 ± 4.0 [6.0, 3.0-17.0] | 7.3 ± 3.3 [8.0, 3.0-12.0] | 6.8 ± 4.1 [5.0, 3.0-17.0] | 0.707 |
| Follow-up, months | ||||
| From initial diagnosis to docetaxel treatment | 31.3 ± 21.6 [25.7, 2.1-94.0] | 20.5 ± 15.0 [18.3, 2.1-41.0] | 33.8 ± 22.2 [26.4, 3.4-94.0] | 0.045 |
| From docetaxel treatment to death or last visit | 21.6 ± 14.7 [17.6, 3.2-86.8] | 12.5 ± 7.8 [10.8, 3.2-26.2] | 23.6 ± 15.1 [19.6, 4.0-86.8] | 0.013 |
| Overall | 52.9 ± 27.2 [5.3-126.4] | 33.0 ± 19.8 [31.1, 5.3-63.1] | 57.4 ± 26.8 [51.7, 21.1-126.4] | 0.003 |
| Type of post-chemotherapy treatment | 0.423 | |||
| None | 51 (71.9) | 9 (69.2) | 42 (72.5) | |
| Abiraterone only | 4 (5.6) | 2 (15.4) | 2 (3.4) | |
| Cabazitaxel only | 3 (4.2) | 1 (7.7) | 2 (3.4) | |
| Enzalutamide only | 7 (9.9) | 1 (7.7) | 6 (10.4) | |
| Abiraterone/Cabazitaxel | 1 (1.4) | 0 | 1 (1.7) | |
| Abiraterone/Enzalutamide | 4 (5.6) | 0 | 4 (6.9) | |
| Abiraterone/Cabazitaxel/Enzalutamide | 1 (1.4) | 0 | 1 (1.7) | |
Data are presented as means ± SD [median, range] or number (%).
SD, standard deviation; CRPC, castration-resistant prostate cancer; PSA, prostate specific antigen; ADT, androgen deprivation therapy; HIFU, high-intensity focused ultrasound.